Maurel M, Howard J, Kissling E, Pozo F, Pérez-Gime. Interim 2023/24 influenza A vaccine effectiveness: VEBIS European primary care and hospital multicentre studies, September 2023 to January 2024. Euro Surveill. 2024 Feb;29(8)
Influenza A viruses circulated in Europe from September 2023 to January 2024, with influenza A(H1N1)pdm09 predominance. We provide interim 2023/24 influenza vaccine effectiveness (IVE) estimates from two European studies, covering 10 countries across primary care (EU-PC) and hospital (EU-H) settings. Interim IVE was higher against A(H1N1)pdm09 than A(H3N2): EU-PC influenza A(H1N1)pdm09 IVE was 53% (95% CI: 41 to 63) and 30% (95% CI: -3 to 54) against influenza A(H3N2). For EU-H, these were 44% (95% CI: 30 to 55) and 14% (95% CI: -32 to 43), respectively.
See Also:
Latest articles in those days:
- From Surfaces to Spillover: Environmental Persistence and Indirect Transmission of Influenza A(H3N8) Virus 7 hours ago
- Immunogenicity and efficacy of commercial poultry avian influenza vaccines against HPAI A(H5N1) clade 2.3.4.4b viruses in Mexico 7 hours ago
- Genomic and structural characterization of a reassortant H9N2 avian influenza virus from a human case 7 hours ago
- Influenza A(H5N8) vaccine induces humoral and cell-mediated immunity against highly pathogenic avian influenza clade 2.3.4.4b A(H5N1) viruses in at-risk individuals 1 days ago
- Host switching mutations in H5N1 influenza hemagglutinin suppress site-specific activation dynamics 1 days ago
[Go Top] [Close Window]
